Cefuroxime-AFT

国: ニュージーランド

言語: 英語

ソース: Medsafe (Medicines Safety Authority)

有効成分:

Cefuroxime sodium 263mg equivalent to 250 mg cefuroxime;  

から入手可能:

AFT Pharmaceuticals Ltd

INN（国際名）:

Cefuroxime sodium 263 mg (equivalent to 250 mg cefuroxime)

投薬量:

250 mg

医薬品形態:

Powder for injection

構図:

Active: Cefuroxime sodium 263mg equivalent to 250 mg cefuroxime  

パッケージ内のユニット:

Vial, glass, Type 1, 10mL with rubber septum, 1 dose unit

クラス:

Prescription

処方タイプ:

Prescription

製:

Qilu Antibiotics Pharmaceutical Co Ltd

適応症:

CEFUROXIME-AFT is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. Indications include: · Respiratory tract infections e.g. acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections.

製品概要:

Package - Contents - Shelf Life: Vial, glass, Type 1, 10mL with rubber septum - 1 dose units - 24 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) - Vial, glass, Type 1, 10mL with rubber septum 10's - 10 dose units - 24 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze)

承認日:

2010-07-26

製品の特徴

1
NEW ZEALAND DATA SHEET
1.
PRODUCT NAME
CEFUROXIME-AFT 250 mg contains Cefuroxime sodium equivalent to
Cefuroxime 250 mg.
CEFUROXIME-AFT 750 mg contains Cefuroxime sodium equivalent to
Cefuroxime 750 mg.
CEFUROXIME-AFT 1.5 g contains Cefuroxime sodium equivalent to
Cefuroxime 1.5 g.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
CEFUROXIME-AFT injection contains either, 250 mg 750 mg, or 1.5 g of
cefuroxime. Each 750
mg vial contains 41 mg sodium
.
For full list of excipients, see Section 6.1 List of Excipients.
3.
PHARMACEUTICALFORM
Powder for injection.
4.
CLINICALPARTICULARS
4.1
THERAPEUTIC INDICATIONS
Cefuroxime is a bactericidal cephalosporin antibiotic which is
resistant to most β-lactamases and
is active against a wide range of Gram-positive and Gram-negative
organisms.
It is indicated for the treatment of infections before the infecting
organism has been identified
or when caused by sensitive bacteria. Susceptibility to cefuroxime
sodium will vary with
geography and time and local susceptibility data should be consulted
where available (see
Section 5.1 Pharmacodynamic properties).
Indications include:
•
Respiratory
tract
infections
for
example,
acute
and
chronic
bronchitis,
infected
bronchiectasis, bacterial pneumonia, lung abscess and post-operative
chest infections.
•
Ear, nose and throat infections for example, sinusitis, tonsillitis,
pharyngitis and otitis
media.
•
Urinary tract infections for example, acute and chronic
pyelonephritis, cystitis and
asymptomatic bacteriuria.
•
Soft-tissue infections for example, cellulitis, erysipelas and wound
infections.
•
Bone and joint infections for example, osteomyelitis and septic
arthritis.
•
Obstetric and gynaecological infections, pelvic inflammatory diseases.
•
Gonorrhoea particularly when penicillin is unsuitable.
•
Other infections including septicaemia, meningitis and peritonitis.
•
Prophylaxis against infection in abdominal, pelvic, orthopaedic,
cardiac, pulmonary,
oesophageal and vascular surgery where there is increased risk from
infec